

Listing of claims

This listing of claims will replace all prior versions and listings of claims in the application:

1. (Currently Amended) An isolated nucleic acid molecule comprising a polynucleotide having a nucleotide sequence ~~at least 95% identical to a sequence selected~~ from the group consisting of:

- (a) a nucleotide sequence encoding a polypeptide comprising amino acids from about 1 to about 1001 in SEQ ID NO:40;
- (b) a nucleotide sequence encoding a polypeptide comprising amino acids from about 2 to about 1001 in SEQ ID NO:40;
- (c) a nucleotide sequence encoding a polypeptide comprising amino acids from about 42 to about 1001 in SEQ ID NO:40;
- (d) a nucleotide sequence encoding a polypeptide having the amino acid sequence encoded by the cDNA clone contained in ATCC Deposit No. PTA-507;
- (e) a nucleotide sequence encoding the mature TR13 polypeptide having the amino acid sequence encoded by the cDNA clone contained in ATCC Deposit No. PTA-507;
- (f) a nucleotide sequence encoding the TR13 extracellular domain encoded by the cDNA clone contained in ATCC Deposit No. PTA-507; and
- ~~(g) a nucleotide sequence encoding the TR13 transmembrane domain encoded by the cDNA clone contained in ATCC Deposit No. PTA-507;~~
- ~~(h) a nucleotide sequence encoding the TR13 intracellular domain encoded by the cDNA clone contained in ATCC Deposit No. PTA-507;~~
- ~~(i) a nucleotide sequence encoding the TR13 receptor extracellular and intracellular domains, encoded by the cDNA clone contained in ATCC Deposit No. PTA-507, with all or part of the transmembrane domain deleted;~~
and
- ~~(g)-(i)~~ (j) a nucleotide sequence complementary to any of the nucleotide sequences in (a), (b), (c), (d), (e), or (f), ~~(g), (h), or (i).~~

2-3. (Canceled)

4. (Currently Amended) The nucleic acid molecule of claim 1, wherein said polynucleotide has the nucleotide sequence is (a)~~in SEQ ID NO:39.~~

5-6. (Canceled)

7. (Currently Amended) The nucleic acid molecule of claim 1, wherein said polynucleotide has the nucleotide sequence is (b)~~in SEQ ID NO:39 encoding the TR13 receptor having the amino acid sequence in SEQ ID NO:40.~~

8-9. (Canceled)

10. (Currently Amended) The nucleic acid molecule of claim 1, wherein said polynucleotide has the nucleotide sequence is (c)~~in SEQ ID NO:39 encoding the mature TR13 receptor having the amino acid sequence in SEQ ID NO:40.~~

11-12. (Canceled)

13. (Currently Amended) The nucleic acid molecule of claim 1, wherein said polynucleotide has the complete nucleotide sequence is (d)~~of the cDNA clone contained in ATCC Deposit No. PTA-507.~~

14-15. (Canceled)

16. (Currently Amended) The nucleic acid molecule of claim 1, wherein said polynucleotide has the nucleotide sequence is (e)~~encoding the TR13 receptor having the amino acid sequence encoded by the cDNA clone contained in ATCC Deposit No. PTA-507.~~

17-18. (Canceled)

19. (Currently Amended) The nucleic acid molecule of claim 1, wherein said polynucleotide has the nucleotide sequence is (f)~~encoding the mature TR13 receptor having~~

~~the amino acid sequence encoded by the cDNA clone contained in ATCC Deposit No. PTA-507.~~

20. (Currently amended) ~~An isolated~~ The nucleic acid molecule ~~comprising a polynucleotide which hybridizes under stringent hybridization conditions to a polynucleotide having a nucleotide sequence identical to a nucleotide sequence in (a), (b), (c), (d), (e), (f), (g), (h), (i), or (j) of claim 1, wherein said polynucleotide which hybridizes does not hybridize under stringent hybridization conditions to a polynucleotide having a nucleotide sequence~~ is (g) consisting of only A residues or of only T residues.

21-33. (Canceled)

34. (Original) A method for making a recombinant vector comprising inserting an isolated nucleic acid molecule of claim 1 into a vector.

35. (Original) A recombinant vector produced by the method of claim 34.

36. (Original) A method of making a recombinant host cell comprising introducing the recombinant vector of claim 35 into a host cell.

37. (Original) A recombinant host cell produced by the method of claim 36.

38. (Original) A recombinant method for producing a TR13 polypeptide, comprising culturing the recombinant host cell of claim 37 under conditions such that said polypeptide is expressed, and recovering said polypeptide.

39-63. (Canceled)

64. (Currently Amended) An isolated nucleic acid molecule comprising a polynucleotide encoding ~~a first amino acid sequence at least 95% identical to a second~~ an amino acid sequence selected from the group consisting of:

(a) amino acid residues 1 to 1001 of SEQ ID NO:40;

- (b) amino acid residues 2 to 1001 of SEQ ID NO:40;
- (c) amino acid residues 42 to 1001 of SEQ ID NO:40;
- ~~(d) amino acid residues 296 to 1001 of SEQ ID NO:40;~~
- (d)(e) amino acid residues 1 to 906 of SEQ ID NO:40;
- (e)(f) amino acid residues 2 to 906 of SEQ ID NO:40; and
- (f)(g) amino acid residues 42 to 906 of SEQ ID NO:40; and
- ~~(h) amino acid residues 296 to 906 of SEQ ID NO:40.~~

65. (Currently Amended) The isolated nucleic acid molecule of claim 64, wherein said first amino acid sequence is ~~at least 95% identical to (a).~~

66-67. (Canceled)

68. (Currently Amended) The isolated nucleic acid molecule of claim 64, wherein said first amino acid sequence is ~~at least 95% identical to (b).~~

69-70. (Canceled)

71. (Currently Amended) The isolated nucleic acid molecule of claim 64, wherein said first amino acid sequence is ~~at least 95% identical to (c).~~

72-76. (Canceled)

77. (Currently Amended) The isolated nucleic acid molecule of claim 64, wherein said first amino acid sequence is (d)~~at least 95% identical to (e).~~

78-79. (Canceled)

80. (Currently Amended) The isolated nucleic acid molecule of claim 64, wherein said first amino acid sequence is (e)~~at least 95% identical to (f).~~

81-82. (Canceled)

83. (Currently Amended) The isolated nucleic acid molecule of claim 64, wherein said first amino acid sequence is (f)~~at least 95% identical to (g).~~

84-88. (Canceled)

89. (Previously presented) An isolated nucleic acid molecule complementary to the isolated nucleic acid molecule of claim 64.

90. (Previously presented) The isolated nucleic acid molecule of claim 64, wherein said nucleic acid is DNA.

91. (Previously presented) The isolated nucleic acid molecule of claim 64, wherein said nucleic acid is RNA.

92. (Previously presented) The isolated nucleic acid molecule of claim 64, wherein said nucleic acid is double-stranded.

93. (Previously presented) The isolated nucleic acid molecule of claim 64, wherein said nucleic acid is single-stranded.

94. (Previously presented) A composition comprising the nucleic acid molecule of claim 64 and a carrier.

95. (Previously presented) The isolated nucleic acid molecule of claim 64 wherein the nucleic acid molecule further comprises a heterologous polynucleotide sequence.

96. (Previously presented) The isolated nucleic acid molecule of claim 95, wherein said heterologous polynucleotide sequence encodes a heterologous polypeptide.

97. (Previously presented) The isolated nucleic acid molecule of claim 96, wherein said heterologous polypeptide is human serum albumin.

98. (Previously presented) The isolated nucleic acid molecule of claim 96, wherein said heterologous polypeptide is a human IgG Fc region.

99. (Previously presented) A recombinant vector comprising the isolated nucleic acid molecule of claim 64.

100. (Previously presented) The recombinant vector of claim 99 wherein the nucleic acid molecule is operably associated with a heterologous regulatory sequence that controls gene expression.

101. (Previously presented) A recombinant host cell comprising the isolated nucleic acid molecule of claim 64.

102. (Previously presented) The recombinant host cell of claim 101 wherein the nucleic acid molecule is operably associated with a heterologous regulatory sequence that controls gene expression.

103. (Currently Amended) A method for producing a polypeptide comprising an amino acid sequence selected from the group consisting of:

- (a) amino acid residues 1 to 1001 of SEQ ID NO:40;
- (b) amino acid residues 2 to 1001 of SEQ ID NO:40;
- (c) amino acid residues 42 to 1001 of SEQ ID NO:40;
- ~~(d) amino acid residues 296 to 1001 of SEQ ID NO:40;~~
- ~~(d)(e)~~ amino acid residues 1 to 906 of SEQ ID NO:40;
- ~~(e)(f)~~ amino acid residues 2 to 906 of SEQ ID NO:40; and
- ~~(f)(g)~~ amino acid residues 42 to 906 of SEQ ID NO:40; and
- ~~(h) amino acid residues 296 to 906 of SEQ ID NO:40;~~

comprising culturing a host cell comprising the nucleic acid molecule of claim 64 under conditions suitable to produce the polypeptide of (a), (b), (c), (d), (e), or ~~(f), (g) or (h)~~ and recovering the polypeptide of (a), (b), (c), (d), (e), or ~~(f), (g) or (h)~~.

104. (Currently Amended) An isolated nucleic acid molecule comprising a polynucleotide encoding a first amino acid sequence at least 95% identical to a second amino acid sequence selected from the group consisting of:

- (a) the amino acid sequence of the full-length TR13 polypeptide encoded by the cDNA contained in ATCC Deposit No. PTA-507;

(b) the amino acid sequence of the full-length TR13 polypeptide encoded by the cDNA contained in ATCC Deposit No. PTA-507, minus the N-terminal methionine residue;

(c) the amino acid sequence of the mature TR13 polypeptide encoded by the cDNA contained in ATCC Deposit No. PTA-507;

(d) the amino acid sequence of the extracellular domain of the full-length TR13 polypeptide encoded by the cDNA contained in ATCC Deposit No. PTA-507;

(e) the amino acid sequence of the extracellular domain of the full-length TR13 polypeptide encoded by the cDNA contained in ATCC Deposit No. PTA-507, minus the N-terminal methionine residue; and

(f) the amino acid sequence of the extracellular domain of the mature TR13 polypeptide encoded by the cDNA contained in ATCC Deposit No. PTA-507;

wherein said polynucleotide encodes a polypeptide which binds Fas ligand.

105. (Previously presented) The isolated nucleic acid molecule of claim 104, wherein said first amino acid sequence is at least 95% identical to (a).

106. (Previously presented) The isolated nucleic acid molecule of claim 105, wherein said first amino acid sequence is (a).

107. (Previously presented) The isolated nucleic acid molecule of claim 104, wherein said first amino acid sequence is at least 95% identical to (b).

108. (Previously presented) The isolated nucleic acid molecule of claim 107, wherein said first amino acid sequence is (b).

109. (Previously presented) The isolated nucleic acid molecule of claim 104, wherein said first amino acid sequence is at least 95% identical to (c).

110. (Previously presented) The isolated nucleic acid molecule of claim 109, wherein said first amino acid sequence is (c).

111. (Previously presented) The isolated nucleic acid molecule of claim 104, wherein said first amino acid sequence is at least 95% identical to (d).

112. (Previously presented) The isolated nucleic acid molecule of claim 111, wherein said first amino acid sequence is (d).

113. (Previously presented) The isolated nucleic acid molecule of claim 104, wherein said first amino acid sequence is at least 95% identical to (e).

114. (Previously presented) The isolated nucleic acid molecule of claim 113, wherein said first amino acid sequence is (e).

115. (Previously presented) The isolated nucleic acid molecule of claim 104, wherein said first amino acid sequence is at least 95% identical to (f).

116. (Previously presented) The isolated nucleic acid molecule of claim 115, wherein said first amino acid sequence is (f).

117. (Previously presented) An isolated nucleic acid molecule complementary to the isolated nucleic acid molecule of claim 104.

118. (Previously presented) The isolated nucleic acid molecule of claim 104, wherein said nucleic acid is DNA.

119. (Previously presented) The isolated nucleic acid molecule of claim 104, wherein said nucleic acid is RNA.

120. (Previously presented) The isolated nucleic acid molecule of claim 104, wherein said nucleic acid is double-stranded.

121. (Previously presented) The isolated nucleic acid molecule of claim 104, wherein said nucleic acid is single-stranded.

122. (Previously presented) A composition comprising the nucleic acid molecule of claim 104 and a carrier.

123. (Previously presented) The isolated nucleic acid molecule of claim 104 wherein the nucleic acid molecule further comprises a heterologous polynucleotide sequence.

124. (Previously presented) The isolated nucleic acid molecule of claim 123, wherein said heterologous polynucleotide sequence encodes a heterologous polypeptide.

125. (Previously presented) The isolated nucleic acid molecule of claim 124, wherein said heterologous polypeptide is human serum albumin.

126. (Previously presented) The isolated nucleic acid molecule of claim 124, wherein said heterologous polypeptide is a human IgG Fc region.

127. (Previously presented) A recombinant vector comprising the isolated nucleic acid molecule of claim 104.

128. (Previously presented) The recombinant vector of claim 127 wherein the nucleic acid molecule is operably associated with a heterologous regulatory sequence that controls gene expression.

129. (Previously presented) A recombinant host cell comprising the isolated nucleic acid molecule of claim 104.

130. (Previously presented) The recombinant host cell of claim 129 wherein the nucleic acid molecule is operably associated with a heterologous regulatory sequence that controls gene expression.

131. (Previously presented) A method for producing a polypeptide comprising an amino acid sequence selected from the group consisting of:

- (a) the amino acid sequence of the full-length TR13 polypeptide encoded by the cDNA contained in ATCC Deposit No. PTA-507;
- (b) the amino acid sequence of the full-length TR13 polypeptide encoded by the cDNA contained in ATCC Deposit No. PTA-507, minus the N-terminal methionine residue;
- (c) the amino acid sequence of the mature TR13 polypeptide encoded by the cDNA contained in ATCC Deposit No. PTA-507;
- (d) the amino acid sequence of the extracellular domain of the full-length TR13 polypeptide encoded by the cDNA contained in ATCC Deposit No. PTA-507;
- (e) the amino acid sequence of the extracellular domain of the full-length TR13 polypeptide encoded by the cDNA contained in ATCC Deposit No. PTA-507, minus the N-terminal methionine residue; and
- (f) the amino acid sequence of the extracellular domain of the mature TR13 polypeptide encoded by the cDNA contained in ATCC Deposit No. PTA-507;

comprising culturing a host cell comprising the nucleic acid molecule of claim 104 under conditions suitable to produce the polypeptide of (a), (b), (c), (d), (e) or (f) and recovering the polypeptide of (a), (b), (c), (d), (e) or (f).

132. (New) An isolated nucleic acid molecule comprising a polynucleotide having a nucleotide sequence at least 95% identical to a sequence selected from the group consisting of:

- (a) a nucleotide sequence encoding a polypeptide comprising amino acids from about 1 to about 1001 in SEQ ID NO:40;
- (b) a nucleotide sequence encoding a polypeptide comprising amino acids from about 2 to about 1001 in SEQ ID NO:40;
- (c) a nucleotide sequence encoding a polypeptide comprising amino acids from about 42 to about 1001 in SEQ ID NO:40;
- (d) a nucleotide sequence encoding a polypeptide having the amino acid sequence encoded by the cDNA clone contained in ATCC Deposit No. PTA-507;
- (e) a nucleotide sequence encoding the mature TR13 polypeptide having the amino acid sequence encoded by the cDNA clone contained in ATCC Deposit No. PTA-507; and

(f) a nucleotide sequence encoding the TR13 extracellular domain encoded by the cDNA clone contained in ATCC Deposit No. PTA-507, wherein said polynucleotide encodes a polypeptide which binds Fas ligand.

133. (New) An isolated nucleic acid molecule having a nucleotide sequence complementary to the nucleotide sequence of claim 132.

134. (New) The nucleic acid molecule of claim 132, wherein said polynucleotide has the nucleotide sequence of (a).

135. (New) The nucleic acid molecule of claim 132, wherein said polynucleotide has the nucleotide sequence of (b).

136. (New) The nucleic acid molecule of claim 132, wherein said polynucleotide has the nucleotide sequence of (c).

137. (New) The nucleic acid molecule of claim 132, wherein said polynucleotide has the nucleotide sequence of (d).

138. (New) The nucleic acid molecule of claim 132, wherein said polynucleotide has the nucleotide sequence of (e).

139. (New) The nucleic acid molecule of claim 132, wherein said polynucleotide has the nucleotide sequence of (f).

140. (New) A method for making a recombinant vector comprising inserting an isolated nucleic acid molecule of claim 132 into a vector.

141. (New) A recombinant vector produced by the method of claim 140.

142. (New) A method of making a recombinant host cell comprising introducing the recombinant vector of claim 141 into a host cell.

143. (New) A recombinant host cell produced by the method of claim 142.

144. (New) A recombinant method for producing a TR13 polypeptide, comprising culturing the recombinant host cell of claim 143 under conditions such that said polypeptide is expressed, and recovering said polypeptide.

145. (New) An isolated nucleic acid molecule comprising a polynucleotide encoding a first amino acid sequence at least 95% identical to a second amino acid sequence selected from the group consisting of:

- (a) amino acid residues 1 to 1001 of SEQ ID NO:40;
- (b) amino acid residues 2 to 1001 of SEQ ID NO:40;
- (c) amino acid residues 42 to 1001 of SEQ ID NO:40;
- (d) amino acid residues 1 to 906 of SEQ ID NO:40;
- (e) amino acid residues 2 to 906 of SEQ ID NO:40; and
- (f) amino acid residues 42 to 906 of SEQ ID NO:40,

wherein said polynucleotide encodes a polypeptide which binds Fas ligand.

146. (New) The isolated nucleic acid molecule of claim 145, wherein said second amino acid sequence is (a).

147. (New) The isolated nucleic acid molecule of claim 145, wherein said second amino acid sequence is (b).

148. (New) The isolated nucleic acid molecule of claim 145, wherein said second amino acid sequence is (c).

149. (New) The isolated nucleic acid molecule of claim 145, wherein said second amino acid sequence is (d).

150. (New) The isolated nucleic acid molecule of claim 145, wherein said second amino acid sequence is (e).

151. (New) The isolated nucleic acid molecule of claim 145, wherein said second amino acid sequence is (f).

152. (New) An isolated nucleic acid molecule complementary to the isolated nucleic acid molecule of claim 145.

153. (New) The isolated nucleic acid molecule of claim 145, wherein said nucleic acid is DNA.

154. (New) The isolated nucleic acid molecule of claim 145 wherein the nucleic acid molecule further comprises a heterologous polynucleotide sequence.

155. (New) The isolated nucleic acid molecule of claim 154, wherein said heterologous polynucleotide sequence encodes a heterologous polypeptide.

156. (New) A recombinant vector comprising the isolated nucleic acid molecule of claim 145.

157. (New) The recombinant vector of claim 156 wherein the nucleic acid molecule is operably associated with a heterologous regulatory sequence that controls gene expression.

158. (New) A recombinant host cell comprising the isolated nucleic acid molecule of claim 145.

159. (New) The recombinant host cell of claim 158 wherein the nucleic acid molecule is operably associated with a heterologous regulatory sequence that controls gene expression.